BACKGROUND: Fibrillar amyloid deposition preferentially affects the frontal lobes, temporal pole/neocortex, and posterior cingulate by age 65 years in APOE ε4 carriers prior to the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), but is it impairing frontally mediated neuropsychological performance? METHODS: A total of 71 ε4 homozygotes (HMZ), 194 ε4 heterozygotes (HTZ), and 356 ε4 noncarriers (NC) who did not differ significantly in mean age (56.6 years), years of education (15.6), gender (70% women), or follow-up duration (6.3 years) had neuropsychological testing every 2 years including the Auditory Verbal Learning Test (AVLT) and frontal/executive tasks sensitive to psychomotor speed, working memory, problem solving, and activity. A subset also received the Iowa Gambling Task (IGT). Findings were then tested in a clinical sample of 27 patients with incident MCI and AD. RESULTS: APOE ε4 carriers had greater acceleration of decline (quadratic effect) than NC on the AVLT (p = 0.04) but not on any frontal test. APOE ε4 HMZ had greater velocity of decline (linear effects) than NC on all mental arithmetic tests: paced auditory serial attention task (PASAT) 3 second (p = 0.01) and 2 second (p = 0.004) versions; and Wechsler Adult Intelligence Scale-Revised arithmetic (p = 0.048). IGT performance did not differ between 12 ε4 HMZ, 27 ε4 HTZ, and 44 NC. Among 27 patients with incident MCI and AD, the PASAT showed progressive decline preceding diagnosis in 50%. CONCLUSIONS: No frontal cognitive effects were as robust as memory decline. APOE ε4 HMZ declined more quickly than NC on mental arithmetic tests related to frontal lobe-mediated working memory ability.
BACKGROUND: Fibrillar amyloid deposition preferentially affects the frontal lobes, temporal pole/neocortex, and posterior cingulate by age 65 years in APOE ε4 carriers prior to the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), but is it impairing frontally mediated neuropsychological performance? METHODS: A total of 71 ε4 homozygotes (HMZ), 194 ε4 heterozygotes (HTZ), and 356 ε4 noncarriers (NC) who did not differ significantly in mean age (56.6 years), years of education (15.6), gender (70% women), or follow-up duration (6.3 years) had neuropsychological testing every 2 years including the Auditory Verbal Learning Test (AVLT) and frontal/executive tasks sensitive to psychomotor speed, working memory, problem solving, and activity. A subset also received the Iowa Gambling Task (IGT). Findings were then tested in a clinical sample of 27 patients with incident MCI and AD. RESULTS:APOE ε4 carriers had greater acceleration of decline (quadratic effect) than NC on the AVLT (p = 0.04) but not on any frontal test. APOE ε4 HMZ had greater velocity of decline (linear effects) than NC on all mental arithmetic tests: paced auditory serial attention task (PASAT) 3 second (p = 0.01) and 2 second (p = 0.004) versions; and Wechsler Adult Intelligence Scale-Revised arithmetic (p = 0.048). IGT performance did not differ between 12 ε4 HMZ, 27 ε4 HTZ, and 44 NC. Among 27 patients with incident MCI and AD, the PASAT showed progressive decline preceding diagnosis in 50%. CONCLUSIONS: No frontal cognitive effects were as robust as memory decline. APOE ε4 HMZ declined more quickly than NC on mental arithmetic tests related to frontal lobe-mediated working memory ability.
Authors: E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance Journal: Science Date: 1993-08-13 Impact factor: 47.728
Authors: Lars M Ittner; Yazi D Ke; Fabien Delerue; Mian Bi; Amadeus Gladbach; Janet van Eersel; Heidrun Wölfing; Billy C Chieng; MacDonald J Christie; Ian A Napier; Anne Eckert; Matthias Staufenbiel; Edna Hardeman; Jürgen Götz Journal: Cell Date: 2010-07-22 Impact factor: 41.582
Authors: Mark Rapoport; Hana N Dawson; Lester I Binder; Michael P Vitek; Adriana Ferreira Journal: Proc Natl Acad Sci U S A Date: 2002-04-16 Impact factor: 11.205
Authors: James A R Nicoll; David Wilkinson; Clive Holmes; Phil Steart; Hannah Markham; Roy O Weller Journal: Nat Med Date: 2003-03-17 Impact factor: 53.440
Authors: Li Zhu; Minghao Zhong; Gregory A Elder; Mary Sano; David M Holtzman; Sam Gandy; Christopher Cardozo; Vahram Haroutunian; Nikolaos K Robakis; Dongming Cai Journal: Proc Natl Acad Sci U S A Date: 2015-09-08 Impact factor: 11.205
Authors: Richard J Caselli; Amylou C Dueck; Dona E C Locke; Leslie C Baxter; Bryan K Woodruff; Yonas E Geda Journal: J Int Neuropsychol Soc Date: 2015-02-09 Impact factor: 2.892
Authors: Richard J Caselli; Kewei Chen; Dona E C Locke; Wendy Lee; Auttawut Roontiva; Dan Bandy; Adam S Fleisher; Eric M Reiman Journal: Alzheimers Dement Date: 2013-04-03 Impact factor: 21.566
Authors: Richard J Caselli; Dona E C Locke; Amylou C Dueck; David S Knopman; Bryan K Woodruff; Charlene Hoffman-Snyder; Rosa Rademakers; Adam S Fleisher; Eric M Reiman Journal: Alzheimers Dement Date: 2013-03-26 Impact factor: 21.566
Authors: Owen A Williams; Yang An; Nicole M Armstrong; Andrea T Shafer; Jessica Helphrey; Melissa Kitner-Triolo; Luigi Ferrucci; Susan M Resnick Journal: Alzheimers Dement Date: 2019-09-24 Impact factor: 21.566
Authors: Emilie T Reas; Gail A Laughlin; Jaclyn Bergstrom; Donna Kritz-Silverstein; Elizabeth Barrett-Connor; Linda K McEvoy Journal: Neuropsychology Date: 2019-02-07 Impact factor: 3.295
Authors: Neha Sinha; Chelsie N Berg; Nicholas J Tustison; Ashlee Shaw; Diane Hill; Michael A Yassa; Mark A Gluck Journal: Neurobiol Aging Date: 2018-05-26 Impact factor: 4.673